Short-Term Intraocular Pressure Trends Following Intravitreal Pegaptanib (Macugen) Injection
Accepted 25 July 2005. published online 10 November 2005.
Purpose
To report the changes and trends in intraocular pressures (IOP) following intravitreal injection of Pegaptanib (Macugen) for the treatment of exudative age-related macular degeneration.
Design
Retrospective chart review.
Methods
Review of 79 patients who underwent 122 consecutive Pegaptanib injections. Analysis of the short-term effect of Pegaptanib injections on IOP was performed.
Results
Baseline mean IOP was 15.73 ± 3.41 mm Hg (mean ± standard deviation) with a range of 9 to 27 mm Hg. Postinjection mean IOP was 24.47 ± 6.29 mm Hg with a range of 8 to 36 mm Hg. Mean IOP change from baseline to roughly 30 minutes after Pegaptanib injection was 8.74 ± 7.23 mm Hg. At the 5- to 7-day follow-up visit, IOP had normalized.
Conclusions
Pegaptanib injection in this limited series seems to be safe from an IOP standpoint in the short-term. IOP monitoring postinjection may not be necessary.
aDepartment of Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois
bBarnes Retina Institute, Department of Ophthalmology and Visual Science, Washington University School of Med, St. Louis, Missouri
Inquiries to Gaurav K. Shah, MD, Barnes Retina Institute, 1600 South Brentwood Blvd, 8th Floor, St Louis, MO 63144; fax: 314-367-1503
Supported by an unrestricted grant from the Research to Prevent Blindness Inc, New York, New York and by the Retina Research and Development Foundation, Barnes Retina Institute, St Louis, Missouri.
ABSTRACT